EMBC - Embecta Corp.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Parsippany,
United States
Type: Equity
EMBC price evolution
EMBC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $243.4 | $167 | $206.4 | |
| Inventory | $185.6 | $153.2 | $149.2 | |
| Total current assets | $781.1 | $710 | $719.5 | |
| Long term investments | ||||
| Property, plant & equipment | $311.6 | $314.8 | $323 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1267.5 | $1199.6 | $1217.8 | |
| Current liabilities | ||||
| Accounts payable | $66.8 | $52.6 | $42.1 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $370.7 | $310.4 | $326.6 | |
| Long term debt | $1621.3 | $1622.6 | $1624 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2031.2 | $1969.2 | $2011.3 | |
| Shareholders' equity | ||||
| Retained earnings | -$504.2 | -$510 | -$530 | |
| Other shareholder equity | -$306.3 | -$299.9 | -$297.5 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2022 | 29 Oct 2021 | 30 Oct 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $160.3 | $22.2 | $151 | $120 |
| Inventory | $152.1 | $122.8 | $118 | $102 |
| Total current assets | $749.1 | $664.7 | $292 | $235 |
| Long term investments | ||||
| Property, plant & equipment | $323.2 | $307.9 | $455 | $467 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1214.4 | $1086.4 | $788 | $738 |
| Current liabilities | ||||
| Accounts payable | $53.5 | $41.4 | $54 | $50 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $353.5 | $301 | $164 | $137 |
| Long term debt | $1625.4 | $1630.7 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2036.1 | $1977.8 | $194 | $166 |
| Shareholders' equity | ||||
| Retained earnings | -$541.1 | -$577.1 | ||
| Other shareholder equity | -$309.1 | -$324.9 | $594 | $572 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $291.1 | $274.5 | $289.3 | $1165 |
| Cost of revenue | ||||
| Gross Profit | $203.1 | $191.2 | $203.9 | $800 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $96.1 | $92.3 | $87.3 | $308 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $11.2 | $14.3 | $17.8 | $80 |
| Interest expense | -$19.5 | -$4.9 | ||
| Net income | ||||
| Net income | $62.4 | $79.6 | $98.8 | $415 |
| Income (for common shares) | ||||
| (in millions $) | 29 Oct 2021 | 30 Oct 2020 | 30 Oct 2019 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1165 | $1086 | $1109 | |
| Cost of revenue | ||||
| Gross Profit | $800 | $763 | $786 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $308 | $276 | $284 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $80 | $58 | $68 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $415 | $428 | $432 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$15.4 | -$10.1 | -$4.3 | -$39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$40.9 | -$44.2 | -$134.5 | -$417 |
| Effect of exchange rate | -$5.6 | -$2.8 | ||
| Change in cash and equivalents | $292.3 | $264.3 | ||
| (in millions $) | 29 Oct 2021 | 30 Oct 2020 | 30 Oct 2019 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$39 | -$42 | -$69 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$417 | -$457 | -$436 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | ||||
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $2.02B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $655.80M |
| Revenue Q/Q | 2.03% |
| Revenue Y/Y | 607.99% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |